Literature DB >> 31654212

Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Tyler J Fraum1, Roberto Cannella2,3, Daniel R Ludwig4, Richard Tsai4, Muhammad Naeem4, Maverick LeBlanc4, Amber Salter5, Allan Tsung6, Anup S Shetty4, Amir A Borhani2, Alessandro Furlan2, Kathryn J Fowler7.   

Abstract

OBJECTIVES: To determine whether the LI-RADS imaging features of primary liver carcinomas (PLCs) other than hepatocellular carcinoma (non-HCC PLCs) differ between patients considered high risk (RF+) versus not high risk (RF-) for HCC and to compare rates of miscategorization as probable or definite HCC between the RF+ and RF- populations.
METHODS: This retrospective study included all pathology-proven non-HCC PLCs imaged with liver-protocol CT or MRI from 2007 to 2017 at two liver transplant centers. Patients were defined per LI-RADS v2018 criteria as RF+ or RF-. Two independent, blinded readers (R1, R2) categorized 265 lesions using LI-RADS v2018. Logistic regression was utilized to assess for differences in imaging feature frequencies between RF+ and RF- patients. Fisher's exact test was used to assess for differences in miscategorization rates.
RESULTS: Non-HCC PLCs were significantly more likely to exhibit nonrim arterial phase hyperenhancement (R1: OR = 2.94; R2: OR = 7.09) and nonperipheral "washout" (R1: OR = 3.65; R2: OR = 7.69) but significantly less likely to exhibit peripheral "washout" (R1: OR = 0.30; R2: OR = 0.10) and delayed central enhancement (R1: OR = 0.18; R2: OR = 0.25) in RF+ patients relative to RF- patients. Consequently, non-HCC PLCs were more often miscategorized as probable or definite HCC in RF+ versus RF- patients (R1: 23.3% vs. 3.6%, p < 0.001; R2: 11.0% vs. 2.6%, p = 0.009).
CONCLUSIONS: Non-HCC PLCs are more likely to mimic HCCs on CT and MRI in the LI-RADS target population than in patients without LI-RADS-defined HCC risk factors. KEY POINTS: • The presence of LI-RADS-defined risk factors for HCC tends to alter the imaging appearances of non-HCC PLCs, resulting in higher frequencies of major features and lower frequencies of LR-M features. • Non-HCC PLCs are more likely to be miscategorized as probable or definite HCC in the LI-RADS target population than in patients without LI-RADS-defined HCC risk factors.

Entities:  

Keywords:  Bile duct neoplasms; Carcinoma, hepatocellular; Cholangiocarcinoma; Liver cirrhosis; Liver neoplasms

Mesh:

Substances:

Year:  2019        PMID: 31654212     DOI: 10.1007/s00330-019-06448-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  40 in total

Review 1.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

2.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

3.  LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.

Authors:  Sang Hyun Choi; Seung Soo Lee; So Hyun Park; Kang Mo Kim; Eunsil Yu; Yangsoon Park; Yong Moon Shin; Moon-Gyu Lee
Journal:  Radiology       Date:  2018-11-13       Impact factor: 11.105

4.  Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI.

Authors:  Kathryn J Fowler; Arman Sheybani; Rex A Parker; Sean Doherty; Elizabeth M Brunt; William C Chapman; Christine O Menias
Journal:  AJR Am J Roentgenol       Date:  2013-08       Impact factor: 3.959

5.  Hepatocellular-cholangiocarcinoma: helical computed tomography findings in 30 patients.

Authors:  Osama Ebied; Michael P Federle; Arye Blachar; Giuseppe Brancatelli; Luigi Grazioli; Dominique Cazals-Hatem; Federica Dondero; Valérie Vilgrain
Journal:  J Comput Assist Tomogr       Date:  2003 Mar-Apr       Impact factor: 1.826

6.  A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of enhancement patterns on dynamics computed tomography before resection.

Authors:  Yuichi Sanada; Shigehiro Shiozaki; Hideki Aoki; Norihisa Takakura; Kazuhiro Yoshida; Yoshiyuki Yamaguchi
Journal:  Hepatol Res       Date:  2005-06-22       Impact factor: 4.288

7.  Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI.

Authors:  Anne R J Péporté; Wieland H Sommer; Konstantin Nikolaou; Maximilian F Reiser; Christoph J Zech
Journal:  Eur J Radiol       Date:  2012-11-16       Impact factor: 3.528

8.  Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Tae Wook Kang; Woo Kyoung Jeong; Soohyun Ahn; Hojeong Won
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

9.  Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark.

Authors:  H T Sorensen; S Friis; J H Olsen; A M Thulstrup; L Mellemkjaer; M Linet; D Trichopoulos; H Vilstrup; J Olsen
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

10.  MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.

Authors:  Jennifer Sammon; Sandra Fischer; Ravi Menezes; Hooman Hosseini-Nik; Sara Lewis; Bachir Taouli; Kartik Jhaveri
Journal:  Cancer Imaging       Date:  2018-02-27       Impact factor: 3.909

View more
  2 in total

1.  Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

Authors:  Xinai Liu; Xiaoyan Ni; Yubo Li; Chun Yang; Yi Wang; Chunzheng Ma; Changwu Zhou; Xin Lu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

2.  Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis.

Authors:  He Linye; Xia Zijing; Peng Wei; He Chao; Li Chuan; Wen Tianfu
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.